New Targeted Lung Cancer Drug, Retevmo, So Effective It Gave Musician His Life Back

Updated February 3rd, 2022

New Targeted Lung Cancer Drug, Retevmo, So Effective It Gave Musician His Life Back

RET+ lung cancers are aggressive and have a poor prognosis, but new targeted drug selpercatinib (Retevmo) benefits more than 90% of patients who have this type of cancer.

NOW
PLAYING
TV Anchor, 53, Opens Up About Her 'Inverted Nipple' And How It Lead To The 'Huge Blow' Of Her Breast Cancer Diagnosis
NOW
PLAYING
Von Hippel-Lindau: Epididymal Cystadenomas
NOW
PLAYING
What Cancer Patients Need to Know About the Covid-19 Vaccine & Treatment in Summer 2022
NOW
PLAYING
Von Hippel-Lindau Syndrome: Retinal Hemangioblastoma
NOW
PLAYING
Fun-Loving Boy, 9, Thought His Sore Leg Was From 'Playing Too Many Video Games:' It Turned Out To Be Cancer
NOW
PLAYING
Von Hippel-Lindau Disease and Tumors

Later Stage Treatment: The Importance of Biomarker Testing

SEE MORE   

  • Changes in cancer cells are called biomarkers and can affect treatment.
  • In lung cancer, there are two sets of biomarkers: driver mutations and PDL1.
  • Normal cells become cancer cells because of driver mutations. PDL1 on cancer cells stops your immune system from killing them.

Later Stage Treatment: The Importance of Biomarker Testing

  • Changes in cancer cells are called biomarkers and can affect treatment.
  • In lung cancer, there are two sets of biomarkers: driver mutations and PDL1.
  • Normal cells become cancer cells because of driver mutations. PDL1 on cancer cells stops your immune system from killing them.
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.